Check out the spin on this promo---

One ASX company Set to Revolutionise the $112 BILLION Cancer-Drug Market

By: Adam Surplice

Industry experts expect that the total market for cancer drugs will top $112 billion by 2020.

That’s why we’re so excited about one small ASX biotech company—and its revolutionary new technology, which could change the way cancer drugs are administered, both here in Australia and all around the world.

Even though this company is still “early stage” it has one product in the market and multiple products in its pipeline, and is approaching profitability at lightning speed.

Then there’s the additional $1 billion market it has just cracked in China and Japan.

And finally the cherry on top — the company’s one of a kind biotechnology, protected by over 100 patents and highly sought after by the world’s biggest healthcare and pharmaceutical companies.

This singular and utterly unique nanoscale technology stands to change the way cancer is treated. It could even help to effect a cure.

Global drug giants are already lining up for access to this innovative technology—inking lucrative multi-year deals which have brought cash pouring in.

Now you see why we’re so excited about this ASX biotech. Particularly the investment potential for shareholders. Cancer-Drug Market

If everything goes to plan, early investors could see as much as 10X returns from here, as the company begins to reach its vast total addressable market (due to be worth $112 billion by 2020!).

When you look at the history of the truly ground-breaking ASX medical technology stocks, the potential looks even greater…

Consider the returns of CSL, ResMed and Cochlear over the last 20 years.

If you’d invested just $10,000 into each of those stocks in 1995, you’d be sitting on more than $3.2 MILLION right now.

To me, the evidence looks overwhelming—this ASX biotech could be set to soar. But you’re going to want to size up this research for yourself as soon as possible.